Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
multi-antigen cmv-modified vaccinia ankara
- Development stage
- Unknown
- Lead developer
- City of Hope Comprehensive Cancer Center
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Multi-antigen CMV-Modified Vaccinia Ankara (CMV-MVA), also known as Triplex, is a recombinant viral vector vaccine designed to prevent or control human cytomegalovirus (HCMV) infection. The vaccine uses the Modified Vaccinia Ankara (MVA) virus as a vector to deliver multiple immunodominant antigens from HCMV—including glycoprotein B (gB), phosphoprotein 65 (pp65), and all five subunits of the envelope pentamer complex. This combination aims to stimulate both humoral and cellular immune responses against HCMV. The primary indications under investigation are prevention of HCMV disease in immunocompromised populations such as transplant recipients and people with HIV[2][5][7][9]. Clinical trials have demonstrated that this approach elicits robust neutralizing antibody production and polyfunctional T cell responses.
- Brand names
- Triplex
- Other names
- cytomegalovirus-modified vaccinia ankara vaccineCMV-MVA Triplexmulti-peptide CMV-Modified Vaccinia Ankara vaccine
02
Targets
pp65 (Cytomegalovirus phosphoprotein 65)gB (Human cytomegalovirus glycoprotein B)HCMV Pentamer (HCMV pentameric glycoprotein complex)
Beyond the preview
Go deeper on multi-antigen cmv-modified vaccinia ankara.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on multi-antigen cmv-modified vaccinia ankara.